<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="782">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>12/09/2005</approvaldate>
  <nctid>NCT00168818</nctid>
  <trial_identification>
    <studytitle>Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery</studytitle>
    <scientifictitle>A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With Half Dose (75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 28-35 Days, in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip Replacement Surgery. RE-NOVATE (Extended Thromboembolism Prevention After Hip Surgery)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2004-001988-21</secondaryid>
    <secondaryid>1160.48</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Thromboembolism</healthcondition>
    <healthcondition>Arthroplasty, Replacement, Hip</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - dabigatran etexilate
Treatment: drugs - dabigatran etexilate
Treatment: drugs - enoxaparin

Experimental: dabigatran etexilate 75 mg - daily dose 150 mg once daily, half a dose on the day of surgery

Experimental: dabigatran etexilate 110 mg - daily dose 220 mg once daily, half a dose on the day of surgery

Active Comparator: enoxaparin - 40 mg once daily


Treatment: drugs: dabigatran etexilate
daily dose 150 mg once daily, half a dose on the day of surgery

Treatment: drugs: dabigatran etexilate
daily dose 150 mg once daily, half a dose on the day of surgery

Treatment: drugs: enoxaparin
40 mg once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period - Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.</outcome>
      <timepoint>First administration until 31-38 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period - Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee</outcome>
      <timepoint>First administration until 31-38 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proximal Deep Vein Thrombosis During Treatment Period - Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee</outcome>
      <timepoint>First administration until 31-38 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Deep Vein Thrombosis During Treatment Period - Total Deep Vein Thrombosis as adjudicated by the VTE events committee</outcome>
      <timepoint>First administration until 31-38 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Symptomatic Deep Vein Thrombosis During Treatment Period - Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee</outcome>
      <timepoint>First administration until 31-38 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pulmonary Embolism During Treatment Period - Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee</outcome>
      <timepoint>First administration until 31-38 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Death During Treatment Period - All cause death, as adjudicated by the VTE events committee</outcome>
      <timepoint>First administration until 31-38 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period - Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).</outcome>
      <timepoint>end of treatment to day 91±7</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period - Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=20g/L in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma greater than or equal to 25 cm²
wound hematoma greater than or equal to 100 cm²
spontaneous nose bleed lasting longer than 5 min
macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention
spontaneous rectal bleeding (more than a spot on toilet paper)
gingival bleeding lasting longer than 5 min
any other bleeding event considered clinically relevant by the investigator
Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</outcome>
      <timepoint>First administration until 31-38 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood Transfusion - Blood transfusion for treated and operated patients on Day of surgery.</outcome>
      <timepoint>Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Volume of Blood Loss - Volume of blood loss for treated and operated patients during surgery.</outcome>
      <timepoint>Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Laboratory Analyses - Frequency of patients with possible clinically significant abnormalities.</outcome>
      <timepoint>First administration to end of study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria

        Inclusion criteria (selected):

          -  Patients (18 years or older) scheduled to undergo a primary, unilateral, elective
             total hip replacement

          -  Written Informed Consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria

        Exclusion criteria (selected):

          -  Patients with an excessive risk of bleeding, for example because of history of
             bleeding diathesis major surgery or trauma within the last 3 months history of
             haemorrhagic stroke or any of the following intracranial pathologies: bleeding,
             neoplasm, AV malformation or aneurysm clinically relevant bleeding or gastric /
             duodenal ulcer within the last 6 months treatment with anticoagulants within 7 days
             prior to joint replacement surgery or anticipated need during the study treatment
             period thrombocytopenia.

          -  Active malignant disease or current cytostatic treatment

          -  Known severe renal insufficiency

          -  Liver disease expected to have any potential impact on survival, or elevated AST or
             ALT &gt; 2x upper limit of normal

          -  Recent unstable cardiovascular disease or history of myocardial infarction within the
             last 3 months

          -  Pre-menopausal women who are pregnant or nursing, or are of child-bearing potential
             and are not practising or do not plan to continue practising acceptable methods of
             birth control

          -  Allergy to radio opaque contrast media or iodine, heparins (incl. heparin induced
             thrombocytopenia) or dabigatran

          -  Contraindications to enoxaparin

          -  Participation in a clinical trial during the last 30 days</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>3494</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,SA,VIC,WA</recruitmentstate>
    <hospital>1160.48.06108 Canberra Hospital - Garren</hospital>
    <hospital>1160.48.06106 St George Public Hospital - Kogarah</hospital>
    <hospital>1160.48.06110 Suite 13 level 4 - Lismore</hospital>
    <hospital>1160.48.06105 Flinders Medical Centre - Bedford Park</hospital>
    <hospital>1160.48.06104 Ecru - Box Hill</hospital>
    <hospital>1160.48.06102 Monash Medical Centre - Clayton</hospital>
    <hospital>1160.48.06101 Emeritus Research - Malvern</hospital>
    <hospital>1160.48.06103 Maroondah Hospital - Ringwood East</hospital>
    <hospital>1160.48.06113 - Windsor</hospital>
    <hospital>1160.48.06111 Haemophillia &amp; Thrombosis Service - Perth</hospital>
    <postcode> - Garren</postcode>
    <postcode> - Kogarah</postcode>
    <postcode> - Lismore</postcode>
    <postcode> - Bedford Park</postcode>
    <postcode> - Box Hill</postcode>
    <postcode> - Clayton</postcode>
    <postcode> - Malvern</postcode>
    <postcode> - Ringwood East</postcode>
    <postcode> - Windsor</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wr. Neustadt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Hasselt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Herentals</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Lanaken</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno-Bohunice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Chomutov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Havlickuv Brod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Jihlava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Kladno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Kolin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Plzen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Pradubice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague 8</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Hellerup</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Hørsholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>København NV</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>København S</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Silkeborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Jyväskylä</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Oulu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Seinäjoki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Amiens cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Roubaix cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Soyaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Mergentheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Garmisch-Partenkirchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kamp-Lintfort</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Markgröningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rheinfelden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Schwandorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sommerfeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wiesbaden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Békéscsaba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Gyula</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kecskemét</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Székesfehérvár</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bergamo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Heemstede</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Helmond</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Hilversum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Sittard</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Bodø</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Bærum Postterminal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Elverum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Skien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Ålesund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Kielce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Mielec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Piekary Slaskie</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Rzeszow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bryanston</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Johannesburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Randburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Sandton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alcorcón (Madrid)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Hospitalet (Barcelona)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Jaén</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Móstoles (Madrid)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Falköping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Göteborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Halmstad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Kalmar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Kungälv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lidköping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Linköping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Mölndal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Varberg</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of this study is to determine the comparative efficacy and safety of two oral
      regimens of dabigatran etexilate, compared to a standard subcutaneous regimen of enoxaparin,
      in prevention of venous thromboembolism in patients with primary elective total hip
      replacement surgery.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00168818</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>